Mainz Biomed N.V. (MYNZ)
NASDAQ: MYNZ · Real-Time Price · USD
4.900
+0.070 (1.45%)
At close: Jan 21, 2025, 4:00 PM
4.888
-0.012 (-0.24%)
After-hours: Jan 21, 2025, 6:57 PM EST
Mainz Biomed Revenue
Mainz Biomed had revenue of $260.39K in the quarter ending June 30, 2024, with 4.60% growth. This brings the company's revenue in the last twelve months to $917.20K, up 16.23% year-over-year. In the year 2023, Mainz Biomed had annual revenue of $895.48K with 69.00% growth.
Revenue (ttm)
$917.20K
Revenue Growth
+16.23%
P/S Ratio
2.64
Revenue / Employee
$12,918
Employees
71
Market Cap
9.81M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 895.48K | 365.60K | 69.00% |
Dec 31, 2022 | 529.88K | -47.47K | -8.22% |
Dec 31, 2021 | 577.35K | 83.78K | 16.98% |
Dec 31, 2020 | 493.57K | 212.17K | 75.40% |
Dec 31, 2019 | 281.39K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
MYNZ News
- 20 hours ago - Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population - GlobeNewsWire
- 4 weeks ago - Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test - GlobeNewsWire
- 5 weeks ago - Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering - GlobeNewsWire
- 5 weeks ago - Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules - GlobeNewsWire
- 7 weeks ago - Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific - Benzinga
- 7 weeks ago - Mainz Biomed Announces Stock Split - GlobeNewsWire
- 3 months ago - Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version - GlobeNewsWire